Keywords: Hyperpolarized MR (Non-Gas), Contrast Agent
Motivation: Isocitrate dehydrogenase (IDH) mutational status is crucial for accurate diagnosis and prognosis of malignant gliomas. However, the current clinical assessment of IDH mutation requires an invasive brain biopsy for pathological testing.
Goal(s): We aimed to perform first in-human MR studies using hyperpolarized [1-13C]alpha-ketoglutarate as a new probe of IDH mutational status via cancer metabolic reprogramming, along with cerebral bioenergetics.
Approach: We acquired 13C MRS data from healthy brain volunteers (N=6) and glioma patients (N=6) who received hyperpolarized aKG.
Results: Feasibility and safety were demonstrated in these 12 studies, with signals observed from [1-13C]alpha-ketoglutarate and its metabolite glutamate in the obtained 13C MRS data.
Impact: MR molecular imaging with the new probe hyperpolarized [1-13C]alpha-ketoglutarate provided novel measurements of aKG metabolism and can investigate glioma IDH mutational status by detecting glutamate or the oncometabolite, 2-hydroxyglutarate.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords